Long-Term Safety and Efficacy of Azetukalner (XEN1101), a Novel, Potent KV7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-Year Open-Label Extension of X-TOLE (P8-9.001)
This abstract reports 30-month data from the X-TOLE 7-year open label extension (OLE) study of azetukalner in participants with focal onset seizures (FOS).
Authors
- Jenny Qian
- Martin J. Brodie (ORCID: https://orcid.org/0000-0003-1781-2892)
- Jacqueline A. French (ORCID: https://orcid.org/0000-0003-2242-8027)
- Emilio Perucca (ORCID: https://orcid.org/0000-0001-8703-223X)
- Gregory N. Beatch
- Cynthia L. Harden
- Christopher Kenney
- Constanza Luzon Rosenblut
- Roger J. Porter (ORCID: https://orcid.org/0009-0005-2240-932X)
Institutions
- The University of Melbourne (AU)
- Western Infirmary (GB)
- California University of Pennsylvania (US)
- Xenon Pharmaceuticals (Canada) (CA)
- Austin Health (AU)
- Monash University (AU)
- New York University (US)
- University of Glasgow (GB)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208587
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00